Image

Global Recombinant Human Growth Hormone (RHGH) Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Recombinant Human Growth Hormone (RHGH) Market, By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Others), Route of Administration (Intravenous, Intramuscular, Subcutaneous, Oral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Other Pharmacy)– Industry Trends and Forecast to 2029

Recombinant Human Growth Hormone (RHGH) Market

Recombinant Human Growth Hormone (RHGH) Market Analysis and Size

Human growth hormone deficiency occurs when the pituitary gland fails to synthesise sufficient concentrations of human growth hormones. This deficiency is treated with subcutaneous injections of recombinant human growth hormones. Growth hormone deficiency can also be caused by genetic disorders such as Prader-Willi syndrome and Turner syndrome, resulting in delayed puberty and shorter-than-average height.

Data Bridge Market Research analyses that the recombinant human growth hormone (rhgh) market was valued at USD 1.32 billion in 2021 and is expected to reach the value of USD 4.11 billion by the year 2029, at a CAGR of 10.30% during the forecast period. The growing demand for small and portable products has had a direct impact on the growth of the market for recombinant human growth hormone (rhgh).

Market Definition

RHGH (rHGH) stands for recombinant human growth hormone, also known as somatropin (INN). It has the same amino acid sequence as endogenous human GH. The fact that RHGH also refers to rhesus monkey GH (RhGH), using the accepted naming convention of Rh for rhesus, is coincidental.

Recombinant Human Growth Hormone (RHGH) Market Size and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Others), Route of Administration (Intravenous, Intramuscular, Subcutaneous, Oral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Other Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

SottoPelle (US), Novartis AG (Switzerland), Orion Pharma AB (Sweden), Full Life Wellness Center (US), BioTE Medical, LLC (US), Merck KGaA (Germany), Pfizer Inc. (US), TherapeuticsMD, Inc. (US), Papillon Medical (Canda), United Pharmacy (US), Noven Pharmaceuticals, Inc. (US), GEA Group Aktiengesellschaft (Germany), Novo Nordisk A/S (Denmark), GeneScience Pharmaceuticals Co., Ltd. (China), Actiza Pharmaceutical Private Limited (India), Defy Medical (US), Neuva Aesthetics (US), ZRT Laboratory (US), Bayer AG (Germany) and Allergan (Ireland)

Opportunities

  • Rising incidence of target conditions
  • Rising government support
  • An increase in off-label usage of human growth hormone

Recombinant Human Growth Hormone (RHGH) Market Dynamics

Drivers

  • Advancement of recombinant human growth hormone

The advancement of recombinant human growth hormone drugs is expected to boost market growth. Other factors that will drive the recombinant human growth hormone (rhGH) market in the forecast period

Growing pituitary dysfunction cases

Increase in pituitary dysfunction cases, an increase in off-label usage of human growth hormone, an increase in R&D investment in recombinant human growth hormone, and the availability of artificial growth hormone.

  • Regulatory Compliance

Maintaining compliance with medical reforms and regulations raises the demand for these solutions.

The increase in the funding by the federal government to drive the adoption of these solutions further influence the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the recombinant human growth hormone (rhgh) market.

Restraints/Challenges

However, the high cost of hGH therapies, as well as various adverse effects associated with hGH, may stymie market growth over the forecast period. For example, UPMC Children's Hospital of Pittsburgh reports that possible side effects of GH hormone therapy include knee, hip, or other joint pain; allergic reactions such as rash, swelling, or hives; and an increase in blood sugar levels.

This recombinant human growth hormone (RHGH) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the recombinant human growth hormone (RHGH) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Recombinant Human Growth Hormone (RHGH) Market

The COVID-19 outbreak is expected to have an effect on the global human growth hormone market. According to a Frontiers article, patients with decreased growth hormone secretion are at risk for COVID-19, which requires attention to aid in COVID-19 prevention. In addition, patients with Prader-Willi syndrome must take precautions to reduce their risk of contracting COVID-19. Furthermore, patients with Prader-Willi syndrome may not exhibit typical symptoms such as a high temperature, and they may also have a higher-than-normal pain threshold, which may delay the diagnosis of COVID-19. Individuals with Turner syndrome are more likely to develop severe illness as a result of the COVID-19 virus. The COVID-19 pandemic has stressed and impacted the world's healthcare systems.

Recent Development

  • Pfizer Inc. launched a Phase III clinical trial in February 2021 to assess the efficacy and safety of somatropin in a group of Japanese Prader-Willi Syndrome patients (PWS).
  • In October 2020, Erasmus Medical Center, in collaboration with Pfizer, the Foundation for Prader-Willi Research, and the Prader-Willi Fonds, will begin a Phase III clinical trial to evaluate the effect of growth hormone treatment (Genotropin) on physical and psychosocial health in adults aged 30 and up with Prader-Willi syndrome.

Global Recombinant Human Growth Hormone (RHGH) Market Scope

The recombinant human growth hormone (rhgh) market is segmented on the basis of application, route of administration and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

  • Growth hormone deficiency
  • Turner syndrome
  • Idiopathic short stature
  • Prader willi syndrome
  • Others

Route of administration

  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Oral

End use

  • Hospital pharmacy
  • Retail pharmacy
  • Clinics
  • Other pharmacy

Recombinant Human Growth Hormone (RHGH) Market Regional Analysis/Insights

The recombinant human growth hormone (rhgh) market is analysed and market size insights and trends are provided by country, application, route of administration and distribution channel as referenced above.

The countries covered in the recombinant human growth hormone (rhgh) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominated the market as a result of factors such as an increase in the geriatric population, the presence of numerous market giants, and new research to develop innovative recombinant human growth hormone. However, Asia-Pacific is expected to have the highest CAGR in terms of revenue during the forecast period, owing to population growth and increased population awareness. Along with this, the continent's economic situation has improved, and healthcare infrastructure has grown.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The recombinant human growth hormone (RHGH) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for recombinant human growth hormone (RHGH) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the recombinant human growth hormone (RHGH) market. The data is available for historic period 2010-2020.

Competitive Landscape and Recombinant Human Growth Hormone (RHGH) Market Share Analysis

The recombinant human growth hormone (RHGH) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to recombinant human growth hormone (RHGH) market.

Some of the major players operating in the recombinant human growth hormone (RHGH) market are

  • SottoPelle (US)
  • Novartis AG (Switzerland)
  • Orion Pharma AB (Sweden)
  • Full Life Wellness Center (US)
  • BioTE Medical, LLC (US)
  • Merck KGaA (Germany)
  • Pfizer Inc. (US)
  • TherapeuticsMD, Inc. (US)
  • Papillon Medical (Canada)
  • United Pharmacy (US)
  • Noven Pharmaceuticals, Inc. (US)
  • GEA Group Aktiengesellschaft (Germany)
  • Novo Nordisk A/S (Denmark)
  • GeneScience Pharmaceuticals Co., Ltd. (China)
  • Actiza Pharmaceutical Private Limited (India)
  • Defy Medical (US)
  • Neuva Aesthetics (US)
  • ZRT Laboratory (US)
  • Bayer AG (Germany)
  • Allergan (Ireland)


SKU-
Why Choose Us


Frequently Asked Questions

The Recombinant Human Growth Hormone (RHGH) Market value is expected USD 4.11 billion by 2029.
The Recombinant Human Growth Hormone (RHGH) Market is to grow at a CAGR of 10.30% during the forecast by 2029.
On the basis of application, the Recombinant Human Growth Hormone (RHGH) Market is segmented into Intravenous, Intramuscular, Subcutaneous, & Oral.
The major players operating in the Recombinant Human Growth Hormone (RHGH) Market are SottoPelle (US), Novartis AG (Switzerland), Orion Pharma AB (Sweden), Full Life Wellness Center (US), BioTE Medical, LLC (US), Merck KGaA (Germany), Pfizer Inc. (US), TherapeuticsMD, Inc. (US), Papillon Medical (Canda), United Pharmacy (US), Noven Pharmaceuticals, Inc. (US), GEA Group Aktiengesellschaft (Germany), Novo Nordisk A/S (Denmark), GeneScience Pharmaceuticals Co., Ltd. (China), Actiza Pharmaceutical Private Limited (India), Defy Medical (US), Neuva Aesthetics (US), ZRT Laboratory (US), Bayer AG (Germany) and Allergan (Ireland).